362 related articles for article (PubMed ID: 23131184)
1. Privileged scaffolds or promiscuous binders: a glance of pyrrolo[2,1-f][1,2,4]triazines and related bridgehead nitrogen heterocycles in medicinal chemistry.
Song Y; Zhan P; Zhang Q; Liu X
Curr Pharm Des; 2013; 19(8):1528-48. PubMed ID: 23131184
[TBL] [Abstract][Full Text] [Related]
2. Pyrrolo[2,1-f][1,2,4]triazines: From C-nucleosides to kinases and back again, the remarkable journey of a versatile nitrogen heterocycle.
Ott GR; Favor DA
Bioorg Med Chem Lett; 2017 Sep; 27(18):4238-4246. PubMed ID: 28801135
[TBL] [Abstract][Full Text] [Related]
3. Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly KM; Shuster DJ; Doweyko AM; Sack JS; Kish K; Kiefer SE; Newitt JA; Zhang H; Marathe PH; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2011 Aug; 21(15):4633-7. PubMed ID: 21705217
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of carbon-11-labeled 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine derivatives as new potential PET tracers for imaging of p38α mitogen-activated protein kinase.
Wang M; Gao M; Zheng QH
Bioorg Med Chem Lett; 2014 Aug; 24(16):3700-5. PubMed ID: 25065491
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of pyrrolo[2,1-f][1,2,4]triazine derivatives as novel hedgehog signaling pathway inhibitors.
Xin M; Zhang L; Tang F; Tu C; Wen J; Zhao X; Liu Z; Cheng L; Shen H
Bioorg Med Chem; 2014 Feb; 22(4):1429-40. PubMed ID: 24486203
[TBL] [Abstract][Full Text] [Related]
6. Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery.
Khwaza V; Mlala S; Oyedeji OO; Aderibigbe BA
Molecules; 2021 Apr; 26(9):. PubMed ID: 33918996
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
9. Heterocyclic Compounds Bearing Triazine Scaffold and Their Biological Significance: A Review.
Verma T; Sinha M; Bansal N
Anticancer Agents Med Chem; 2020; 20(1):4-28. PubMed ID: 31746306
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Activities of 5, 6-Diaryl/heteroaryl-3-substituted-1, 2, 4- triazines as a Privileged Scaffold in Drug Development.
Khatir ZZ; Irannejad H
Mini Rev Med Chem; 2021; 21(19):2874-2928. PubMed ID: 33719962
[TBL] [Abstract][Full Text] [Related]
11. 1,3,5-Triazine-based analogues of purine: from isosteres to privileged scaffolds in medicinal chemistry.
Lim FP; Dolzhenko AV
Eur J Med Chem; 2014 Oct; 85():371-90. PubMed ID: 25105925
[TBL] [Abstract][Full Text] [Related]
12. 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.
Ott GR; Wells GJ; Thieu TV; Quail MR; Lisko JG; Mesaros EF; Gingrich DE; Ghose AK; Wan W; Lu L; Cheng M; Albom MS; Angeles TS; Huang Z; Aimone LD; Ator MA; Ruggeri BA; Dorsey BD
J Med Chem; 2011 Sep; 54(18):6328-41. PubMed ID: 21859094
[TBL] [Abstract][Full Text] [Related]
13. The chemistry and biological activity of heterocycle-fused quinolinone derivatives: A review.
Shiro T; Fukaya T; Tobe M
Eur J Med Chem; 2015 Jun; 97():397-408. PubMed ID: 25532473
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the pyrrolo[2,1-f][1,2,4]triazine nucleus as a new kinase inhibitor template.
Hunt JT; Mitt T; Borzilleri R; Gullo-Brown J; Fargnoli J; Fink B; Han WC; Mortillo S; Vite G; Wautlet B; Wong T; Yu C; Zheng X; Bhide R
J Med Chem; 2004 Jul; 47(16):4054-9. PubMed ID: 15267243
[TBL] [Abstract][Full Text] [Related]
15. Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.
Mesaros EF; Angeles TS; Albom MS; Wagner JC; Aimone LD; Wan W; Lu L; Huang Z; Olsen M; Kordwitz E; Haltiwanger RC; Landis AJ; Cheng M; Ruggeri BA; Ator MA; Dorsey BD; Ott GR
Bioorg Med Chem Lett; 2015 Mar; 25(5):1047-52. PubMed ID: 25655723
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
[TBL] [Abstract][Full Text] [Related]
18. An unprecedented nitrogen elimination reaction: mechanistic studies using 15N-labeled 4-amino-7-benzylpyrrolo[2,3-d][1,2,3]triazine-5-carbonitrile.
Migawa MT; Townsend LB
Org Lett; 1999 Aug; 1(4):537-9. PubMed ID: 10823187
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Wittman MD; Carboni JM; Yang Z; Lee FY; Antman M; Attar R; Balimane P; Chang C; Chen C; Discenza L; Frennesson D; Gottardis MM; Greer A; Hurlburt W; Johnson W; Langley DR; Li A; Li J; Liu P; Mastalerz H; Mathur A; Menard K; Patel K; Sack J; Sang X; Saulnier M; Smith D; Stefanski K; Trainor G; Velaparthi U; Zhang G; Zimmermann K; Vyas DM
J Med Chem; 2009 Dec; 52(23):7360-3. PubMed ID: 19778024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
